VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
KMDAKamada Ltd.
$7.31$422M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

KMDA logoKamada Ltd.(KMDA)Earnings, Financials & Key Ratios

KMDA•NASDAQ
19.8× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryVaccines and biodefense products
AboutKamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Show more
  • Revenue$180M+12.1%
  • EBITDA$41M+21.5%
  • Net Income$20M+39.7%
  • EPS (Diluted)0.37+48.0%
  • Gross Margin42.34%-2.6%
  • EBITDA Margin22.8%+8.4%
  • Operating Margin14.54%+16.7%
  • Net Margin11.19%+24.6%
  • ROE7.64%+33.0%

KMDA Key Insights

Kamada Ltd. (KMDA) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Healthy dividend yield of 2.9%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when KMDA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

KMDA Price & Volume

Kamada Ltd. (KMDA) stock price & volume — 10-year historical chart

Loading chart...

KMDA Growth Metrics

Kamada Ltd. (KMDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years9.92%
5 Years6.25%
3 Years11.74%
TTM8.64%

Profit CAGR

10 Years-
5 Years3.34%
3 Years-
TTM26.8%

EPS CAGR

10 Years-
5 Years-2.03%
3 Years-
TTM20.34%

Return on Capital

10 Years6.9%
5 Years3.9%
3 Years6.02%
Last Year8.02%

KMDA Recent Earnings

Kamada Ltd. (KMDA) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.07-41.7%
$0.12
Rev
$45M-3.2%
$47M
Q2 2026
Mar 11, 2026
Metric
Actual
Est
EPS
$0.06-33.3%
$0.09
Rev
$45M-1.6%
$45M
Q4 2025
Nov 10, 2025
Metric
Actual
Est
EPS
$0.09-10.0%
$0.10
Rev
$47M-68.1%
$148M
Q3 2025
Aug 13, 2025
Metric
Actual
Est
EPS
$0.13+44.4%
$0.09
Rev
$45M-71.1%
$155M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.07vs $0.12-41.7%
$45Mvs $47M-3.2%
Q2 2026Mar 11, 2026
$0.06vs $0.09-33.3%
$45Mvs $45M-1.6%
Q4 2025Nov 10, 2025
$0.09vs $0.10-10.0%
$47Mvs $148M-68.1%
Q3 2025Aug 13, 2025
$0.13vs $0.09+44.4%
$45Mvs $155M-71.1%
Based on last 12 quarters of dataView full earnings history →

KMDA Peer Comparison

Kamada Ltd. (KMDA) competitors in Vaccines and biodefense products — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
ADMA logoADMAADMA Biologics, Inc.Direct Competitor1.93B8.3113.8519.63%32.43%38.97%0.17
GRFS logoGRFSGrifols, S.A.Direct Competitor6.26B7.4011.280.2%5.58%5.43%1.15
BIO logoBIOBio-Rad Laboratories, Inc.Direct Competitor7.63B282.4410.130.65%6.52%2.4%0.21
BHVN logoBHVNBiohaven Ltd.Product Competitor1.44B13.57-1.98-8.66%5.36
RARE logoRAREUltragenyx Pharmaceutical Inc.Product Competitor2.7B27.44-4.7120.13%-91.03%-6.08%
PRTA logoPRTAProthena Corporation plcProduct Competitor467.51M8.93-1.97-92.84%-260.92%-49.88%0.05
ACAD logoACADACADIA Pharmaceuticals Inc.Product Competitor3.7B21.629.4411.87%34.3%35.65%0.04
FOLD logoFOLDAmicus Therapeutics, Inc.Product Competitor4.55B14.49-164.8520.05%-4.27%-12.02%1.76

Compare KMDA vs Peers

Kamada Ltd. (KMDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ADMA

Most directly comparable listed peer for KMDA.

Scale Benchmark

vs GILD

Larger-name benchmark to compare KMDA against a more recognizable public peer.

Peer Set

Compare Top 5

vs ADMA, GRFS, BIO, BHVN

KMDA Income Statement

Kamada Ltd. (KMDA) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
102.83M114.47M127.19M133.25M103.64M129.34M142.52M160.95M180.46M181.68M
Revenue Growth %
32.69%11.32%11.11%4.76%-22.22%24.79%10.19%12.93%12.12%8.64%
Cost of Goods Sold
70.74M73M77.45M85.69M73.31M82.64M87.03M90.99M104.05M106.91M
COGS % of Revenue
68.79%63.77%60.89%64.31%70.74%63.89%61.06%56.53%57.66%-
Gross Profit
32.09M▲ 0%
41.47M▲ 29.2%
49.74M▲ 19.9%
47.55M▼ 4.4%
30.33M▼ 36.2%
46.7M▲ 54.0%
55.49M▲ 18.8%
69.97M▲ 26.1%
76.41M▲ 9.2%
74.77M▲ 0%
Gross Margin %
31.21%36.23%39.11%35.69%29.26%36.11%38.94%43.47%42.34%41.16%
Gross Profit Growth %
48.21%29.24%19.93%-4.39%-36.22%53.99%18.81%26.09%9.2%-
Operating Expenses
24.64M22.21M26.95M28.32M31.02M42.17M45.43M49.92M50.17M49.38M
OpEx % of Revenue
23.97%19.41%21.19%21.25%29.93%32.61%31.87%31.01%27.8%-
Selling, General & Admin
12.67M12.15M12.85M14.66M17.55M25.06M27.45M30.83M33.84M35.12M
SG&A % of Revenue
12.32%10.62%10.1%11%16.93%19.37%19.26%19.16%18.75%-
Research & Development
11.97M9.75M13.06M13.61M11.36M13.17M13.93M15.19M12.99M10.93M
R&D % of Revenue
11.64%8.52%10.27%10.21%10.96%10.18%9.78%9.43%7.2%-
Other Operating Expenses
0997K1.05M49K2.12M3.94M4.04M3.9M3.34M1000K
Operating Income
7.44M▲ 0%
19.26M▲ 158.7%
22.78M▲ 18.3%
19.24M▼ 15.6%
-696K▼ 103.6%
4.53M▲ 751.1%
10.06M▲ 122.1%
20.05M▲ 99.2%
26.23M▲ 30.8%
25.39M▲ 0%
Operating Margin %
7.24%16.82%17.91%14.44%-0.67%3.5%7.06%12.46%14.54%13.98%
Operating Income Growth %
227.44%158.72%18.3%-15.57%-103.62%751.15%122.07%99.23%30.83%-
EBITDA
11.09M22.82M27.3M24.48M4.91M16.69M21.53M33.86M41.15M40.55M
EBITDA Margin %
10.79%19.94%21.47%18.37%4.74%12.9%15.11%21.04%22.8%22.32%
EBITDA Growth %
546.69%105.71%19.64%-10.33%-79.93%239.65%29.05%57.24%21.54%6.74%
D&A (Non-Cash Add-back)
3.65M3.56M4.52M5.25M5.61M12.15M11.47M13.81M14.92M15.16M
EBIT
7.6M19.9M23.27M20.17M-1.6M-1.34M10.06M13.99M24.33M23.11M
Net Interest Income
418K461.82K853K761K12K-823K-710K1.46M1.06M952K
Interest Income
500K788.95K1.15M1.03M295K91K588K2.12M1.92M1.81M
Interest Expense
82K327.13K293K266K283K914K1.3M660K864K860K
Other Income/Expense
-274K1.08M197K-672K-1.19M-6.79M-1.64M-6.72M-2.77M-3.15M
Pretax Income
7.17M▲ 0%
20.34M▲ 183.7%
22.98M▲ 13.0%
18.57M▼ 19.2%
-1.89M▼ 110.2%
-2.26M▼ 19.8%
8.43M▲ 473.1%
13.33M▲ 58.2%
23.47M▲ 76.0%
22.25M▲ 0%
Pretax Margin %
6.97%17.77%18.07%13.93%-1.82%-1.75%5.91%8.28%13%12.24%
Income Tax
269K-1.96M730K1.43M345K62K145K-1.13M3.27M1.88M
Effective Tax Rate %
3.75%-9.61%3.18%7.68%-18.3%-2.74%1.72%-8.46%13.93%8.45%
Net Income
6.9M▲ 0%
22.3M▲ 223.1%
22.25M▼ 0.2%
17.14M▼ 23.0%
-2.23M▼ 113.0%
-2.32M▼ 4.1%
8.28M▲ 456.9%
14.46M▲ 74.6%
20.2M▲ 39.7%
20.37M▲ 0%
Net Margin %
6.71%19.48%17.49%12.86%-2.15%-1.79%5.81%8.99%11.19%11.21%
Net Income Growth %
202.5%223.08%-0.2%-22.97%-113.01%-4.08%456.92%74.58%39.66%26.8%
Net Income (Continuing)
6.9M22.3M22.25M17.14M-2.23M-2.32M8.28M14.46M20.2M20.37M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
0.18▲ 0%
0.55▲ 205.6%
0.57▲ 3.6%
0.41▼ 28.1%
-0.05▼ 112.1%
-0.05▼ 4.0%
0.15▲ 389.6%
0.25▲ 66.7%
0.37▲ 48.0%
0.35▲ 0%
EPS Growth %
200%205.56%3.64%-28.07%-112.15%-4.02%389.58%66.67%48%20.34%
EPS (Basic)
0.180.550.570.42-0.05-0.050.170.250.38-
Diluted Shares Outstanding
38.05M40.54M40.58M44.59M44.77M44.82M53.68M57.82M58.35M59.03M
Basic Shares Outstanding
37.97M40.28M40.32M44.14M44.77M44.82M48.83M57.49M57.65M59.03M
Dividend Payout Ratio
--------61.81%-

KMDA Balance Sheet

Kamada Ltd. (KMDA) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
96.88M110.89M143.56M177.91M130.04M139M169.96M184.35M193.12M199.24M
Cash & Short-Term Investments
43.02M50.59M73.91M109.27M18.59M34.26M55.64M78.44M75.48M73.15M
Cash Only
12.68M18.09M42.66M70.2M18.59M34.26M55.64M78.44M75.48M32.92M
Short-Term Investments
30.34M32.5M31.25M39.07M0000040.23M
Accounts Receivable
31.97M29.5M25.23M23.05M35.56M28.36M21.29M23.2M29.05M40.65M
Days Sales Outstanding
113.4994.0672.463.15125.2480.0254.5252.658.7570.43
Inventory
21.07M29.32M43.17M43.04M71.83M72.52M88.48M78.82M84.96M85.44M
Days Inventory Outstanding
108.72146.59203.46183.33357.61320.3371.08316.19298.03288.4
Other Current Assets
0015K448K73K0149K49K00
Total Non-Current Assets
25.23M27.23M30.23M32.75M188.62M183.37M184.94M187.91M185.67M183.79M
Property, Plant & Equipment
25.18M25M28.57M29.12M29.4M28.73M35.98M45.86M50.28M50.37M
Fixed Asset Turnover
4.08x4.58x4.45x4.58x3.53x4.50x3.96x3.51x3.59x3.73x
Goodwill
000030.31M30.31M30.31M30.31M30.32M30.31M
Intangible Assets
0123K298K1.49M123.28M116.7M109.64M101.86M96.12M95.68M
Long-Term Investments
0-123K0000007.55M15.32M
Other Non-Current Assets
49K174K54K2.14M5.63M7.64M9.01M9.38M1.42M7.43M
Total Assets
122.11M▲ 0%
138.12M▲ 13.1%
173.8M▲ 25.8%
210.66M▲ 21.2%
318.67M▲ 51.3%
322.38M▲ 1.2%
354.91M▲ 10.1%
372.25M▲ 4.9%
378.79M▲ 1.8%
383.02M▲ 0%
Asset Turnover
0.84x0.83x0.73x0.63x0.33x0.40x0.40x0.43x0.48x0.48x
Asset Growth %
22.48%13.11%25.83%21.21%51.27%1.16%10.09%4.89%1.76%16.15%
Total Current Liabilities
29.4M23.57M32.74M24.97M54.06M75.7M49.59M49.39M47.4M59.78M
Accounts Payable
18.04M17.29M24.83M16.11M25.1M32.92M24.8M27.73M23.25M21.94M
Days Payables Outstanding
93.0686.43117.0268.62124.98145.39104.03111.2681.5581.2
Short-Term Debt
614K452K489K238K2.63M4.44M002.12M0
Deferred Revenue (Current)
4.93M461K589K222K247K236K325K171K01.27M
Other Current Liabilities
1.08M553K5.67M7.03M24.33M36.48M22.54M19.4M11.77M10.64M
Current Ratio
3.30x4.70x4.39x7.13x2.41x1.84x3.43x3.73x4.07x3.33x
Quick Ratio
2.58x3.46x3.07x5.40x1.08x0.88x1.64x2.14x2.28x1.90x
Cash Conversion Cycle
129.15154.21158.84177.86357.87254.93321.57257.53275.23277.63
Total Non-Current Liabilities
3.22M2.17M5.74M7.06M87.79M70.65M61.29M63.4M62.26M63.86M
Long-Term Debt
1.37M688K257K36K17.41M12.96M0000
Capital Lease Obligations
028K3.98M3.59M3.16M2.18M7.44M9.43M9.44M37.99M
Deferred Tax Liabilities
21.06M16.92M0000001.65M6.9M
Other Non-Current Liabilities
1.14M787K1.27M1.41M67.2M55.51M53.85M53.97M51.17M51.55M
Total Liabilities
32.62M25.74M38.48M32.03M141.84M146.36M110.89M112.79M109.66M123.63M
Total Debt
1.98M1.28M5.75M4.94M24.35M20.6M8.82M11.06M11.56M11.64M
Net Debt
-10.7M-16.82M-36.91M-65.26M5.76M-13.66M-46.82M-67.37M-63.92M-21.28M
Debt / Equity
0.02x0.01x0.04x0.03x0.14x0.12x0.04x0.04x0.04x0.04x
Debt / EBITDA
0.18x0.06x0.21x0.20x4.96x1.23x0.41x0.33x0.28x0.29x
Net Debt / EBITDA
-0.96x-0.74x-1.35x-2.67x1.17x-0.82x-2.17x-1.99x-1.55x-0.52x
Interest Coverage
92.64x60.83x79.43x75.83x-5.66x-1.47x7.75x21.20x28.16x26.87x
Total Equity
89.49M▲ 0%
112.38M▲ 25.6%
135.32M▲ 20.4%
178.64M▲ 32.0%
176.82M▼ 1.0%
176.02M▼ 0.5%
244.02M▲ 38.6%
259.46M▲ 6.3%
269.13M▲ 3.7%
259.39M▲ 0%
Equity Growth %
34.08%25.57%20.42%32.01%-1.02%-0.45%38.63%6.33%3.72%14.08%
Book Value per Share
2.352.773.334.013.953.934.554.494.614.39
Total Shareholders' Equity
89.49M112.38M135.32M178.64M176.82M176.02M244.02M259.46M269.13M259.39M
Common Stock
10.4M10.41M10.43M11.71M11.72M11.73M15.02M15.03M15.08M15.08M
Retained Earnings
-104.56M-83.02M-61.07M-43.93M-46.16M-48.48M-40.2M-25.74M-17.08M-27.36M
Treasury Stock
0000000000
Accumulated OCI
-3.79M-3.51M-3.7M-3.45M-3.58M-3.23M-3.08M-3.08M2.78M-3.12M
Minority Interest
0000000000

KMDA Cash Flow Statement

Kamada Ltd. (KMDA) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
3.89M10.55M28.44M19.11M-9.17M28.59M4.32M47.59M27.59M25.96M
Operating CF Margin %
3.78%9.21%22.36%14.34%-8.85%22.1%3.03%29.57%15.29%-
Operating CF Growth %
105.06%171.11%169.69%-32.83%-147.98%411.82%-84.91%1002.99%-42.03%-77.21%
Net Income
6.9M22.3M22.95M17.14M-2.32M-2.32M8.28M14.46M21.86M20.37M
Depreciation & Amortization
3.52M3.7M4.66M4.9M5.83M12.15M12.71M13.81M16.15M15.24M
Stock-Based Compensation
483K948K0977K01.15M1.31M874K01.01M
Deferred Taxes
269K-1.96M748.91K1.43M062K145K-1.13M0707K
Other Non-Cash Items
650K-380K1.85M1.77M2.3M5.89M60K8.16M8.72M5.62M
Working Capital Changes
-7.94M-14.07M-1.77M-7.1M-14.98M11.65M-18.2M11.41M-19.14M-17.05M
Change in Receivables
-9.97M2.31M5.06M1.45M-15.07M5.68M9.5M-908K-5.92M-6.58M
Change in Inventory
4.52M-8.25M-14.29M1.16M-2.47M-1.36M-19.69M9.66M-6.63M-6.9M
Change in Payables
-556K-1.12M6.46M-9.56M8.23M7.05M-8.88M1.23M-7.44M-4.77M
Cash from Investing
-15.89M-5.18M-581.8K-13.13M-63.46M-3.78M-5.84M-10.74M-10.65M-49.66M
Capital Expenditures
-4.45M-2.88M-2.37M-5.49M-3.88M-3.78M-5.85M-10.74M-10.66M-9.43M
CapEx % of Revenue
4.33%2.52%1.87%4.12%3.74%2.93%4.1%6.67%5.91%5.19%
Acquisitions
62.16K28.86K9.28K0-100.21M0008.66K-166
Investments
----------
Other Investing
-11.44M-2.29M07K007K1K00
Cash from Financing
15.32M-587K-1.58M23.36M19.33M-9.34M22.68M-13.91M-19.86M-18.65M
Debt Issued (Net)
-251K-596K-491.02K-1.59M20.58M-3.73M-18.26M-1.25M-972K-1.35M
Equity Issued (Net)
15.57M016.5K24.89M19.75K058.23M054.12K62
Dividends Paid
00000000-12.49M-11.29M
Share Repurchases
0000000000
Other Financing
3K9K-1.1M64K-1.27M-5.62M-17.3M-12.66M-6.45M-6.01M
Net Change in Cash
2.71M▲ 0%
5.41M▲ 99.5%
24.57M▲ 354.0%
27.54M▲ 12.1%
-51.58M▼ 287.3%
15.67M▲ 130.4%
21.38M▲ 36.4%
22.79M▲ 6.6%
-2.95M▼ 112.9%
-43.09M▲ 0%
Free Cash Flow
-559K▲ 0%
7.66M▲ 1470.7%
26.07M▲ 240.2%
13.62M▼ 47.8%
-13.04M▼ 195.8%
24.8M▲ 290.1%
-1.53M▼ 106.2%
36.85M▲ 2500.9%
16.93M▼ 54.1%
16.53M▲ 0%
FCF Margin %
-0.54%6.69%20.5%10.22%-12.59%19.18%-1.08%22.9%9.38%9.1%
FCF Growth %
24.87%1470.66%240.23%-47.76%-195.8%290.13%-106.19%2500.91%-54.05%-54.76%
FCF per Share
-0.010.190.640.31-0.290.55-0.030.640.290.28
FCF Conversion (FCF/Net Income)
0.56x0.47x1.28x1.11x4.11x-12.32x0.52x3.29x1.37x0.81x
Interest Paid
0000000000
Taxes Paid
0000000000

KMDA Key Ratios

Kamada Ltd. (KMDA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
8.83%22.09%17.97%10.92%-1.25%-1.32%3.94%5.74%7.64%7.73%
Return on Invested Capital (ROIC)
8.13%16.57%17.62%13.63%-0.35%1.97%4.2%7.73%9.9%8.93%
Gross Margin
31.21%36.23%39.11%35.69%29.26%36.11%38.94%43.47%42.34%41.16%
Net Margin
6.71%19.48%17.49%12.86%-2.15%-1.79%5.81%8.99%11.19%11.21%
Debt / Equity
0.02x0.01x0.04x0.03x0.14x0.12x0.04x0.04x0.04x0.04x
Interest Coverage
92.64x60.83x79.43x75.83x-5.66x-1.47x7.75x21.20x28.16x26.87x
FCF Conversion
0.56x0.47x1.28x1.11x4.11x-12.32x0.52x3.29x1.37x0.81x
Revenue Growth
32.69%11.32%11.11%4.76%-22.22%24.79%10.19%12.93%12.12%8.64%
Related:KMDA Dividend History·KMDA Revenue History·KMDA Price History·KMDA P/E History·KMDA Financial Ratios·KMDA Institutional Holders

KMDA Frequently Asked Questions

Kamada Ltd. (KMDA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Kamada Ltd. (KMDA) reported $181.7M in revenue for fiscal year 2025. This represents a 1094% increase from $15.2M in 2008.

Kamada Ltd. (KMDA) grew revenue by 12.1% over the past year. This is steady growth.

Yes, Kamada Ltd. (KMDA) is profitable, generating $20.4M in net income for fiscal year 2025 (11.2% net margin).

Dividend & Returns

Yes, Kamada Ltd. (KMDA) pays a dividend with a yield of 2.93%. This makes it attractive for income-focused investors.

Kamada Ltd. (KMDA) has a return on equity (ROE) of 7.6%. This is below average, suggesting room for improvement.

Kamada Ltd. (KMDA) generated $16.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in KMDA back in 2008?

Total return calculator · dividends reinvested · 18+ years of data

See returns →

How much would $100/month in KMDA be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →